FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048164517> ?p ?o ?g. }

• W3048164517 endingPage "1367" @default.
• W3048164517 startingPage "1358" @default.
• W3048164517 abstract "Histidine is an essential amino acid with health benefits that may warrant histidine supplementation; however, the clinical safety of histidine intake above the average dietary intake (1.52-5.20 g/d) needs to be vetted.We aimed to determine the tolerance to graded dosages of histidine in a healthy adult population.Healthy adults aged 21-50 y completed graded dosages of histidine supplement (4, 8, and 12 g/d, Study 1) (n = 20 men and n = 20 women) and/or a 16-g/d dosage of histidine (Study 2, n = 21 men and n = 19 women); 27 participants (n = 12 men and n = 15 women) completed both studies. After study enrollment and baseline measures, participants consumed encapsulated histidine for 4 wk followed by a 3-wk recovery period. Primary outcomes included vitals, select biochemical analytes, anthropometry, serum zinc, and body composition (via DXA).No changes in vitals or body composition occurred with histidine supplementation in either study. Plasma histidine (measured in subjects who completed all dosages for Studies 1 and 2) was elevated at the 12- and 16-g/d dosages (compared with 0-8 g/d, P < 0.05) and blood urea nitrogen increased with dosage (P = 0.013) and time (P < 0.001) in Study 1 and with time in Study 2 (P < 0.001). In Study 1, mean ferritin concentrations were lower in 12 g/d (46.0 ng/mL; 95% CI: 34.8, 60.9 ng/mL) than in 4 g/d (51.6 ng/mL; 95% CI: 39.0, 68.4 ng/mL; P = 0.038). In Study 2, 16 g/d increased mean aspartate aminotransferase from baseline (19 U/L; 95% CI: 17, 22 U/L) to week 4 (24 U/L; 95% CI: 21, 27 U/L; P < 0.001) and mean serum zinc decreased from baseline (0.75 μg/dL; 95% CI: 0.71, 0.80 μg/dL) to week 4 (0.70 μg/dL; 95% CI: 0.66, 0.74 μg/dL; P = 0.011).Although values remained within the normal reference ranges for all analytes measured, in all dosages tested, the human no-observed adverse effect level was determined to be 8 g/d owing to changes in blood parameters at the 12-g/d dosage.This trial was registered at clinicaltrials.gov as NCT04142294." @default.
• W3048164517 created "2020-08-13" @default.
• W3048164517 creator A5016726863 @default.
• W3048164517 creator A5022380997 @default.
• W3048164517 creator A5022898660 @default.
• W3048164517 creator A5023538492 @default.
• W3048164517 creator A5037206327 @default.
• W3048164517 creator A5042375667 @default.
• W3048164517 creator A5052879720 @default.
• W3048164517 creator A5073182350 @default.
• W3048164517 creator A5079030452 @default.
• W3048164517 date "2020-08-07" @default.
• W3048164517 modified "2023-10-10" @default.
• W3048164517 title "Tolerance to graded dosages of histidine supplementation in healthy human adults" @default.
• W3048164517 cites W1636283872 @default.
• W3048164517 cites W1931522059 @default.
• W3048164517 cites W1954588496 @default.
• W3048164517 cites W2015920118 @default.
• W3048164517 cites W2028449239 @default.
• W3048164517 cites W2072529114 @default.
• W3048164517 cites W2081034259 @default.
• W3048164517 cites W2093912923 @default.
• W3048164517 cites W2118481472 @default.
• W3048164517 cites W2126357176 @default.
• W3048164517 cites W2131499497 @default.
• W3048164517 cites W2149097284 @default.
• W3048164517 cites W2156917860 @default.
• W3048164517 cites W2168335626 @default.
• W3048164517 cites W2190313991 @default.
• W3048164517 cites W2235894085 @default.
• W3048164517 cites W2238215445 @default.
• W3048164517 cites W2270539348 @default.
• W3048164517 cites W2277703644 @default.
• W3048164517 cites W2474357441 @default.
• W3048164517 cites W2761406325 @default.
• W3048164517 cites W2808012165 @default.
• W3048164517 cites W2810417945 @default.
• W3048164517 cites W2866743330 @default.
• W3048164517 cites W2972667145 @default.
• W3048164517 cites W3119657077 @default.
• W3048164517 cites W4206172277 @default.
• W3048164517 cites W4211062186 @default.
• W3048164517 doi "https://doi.org/10.1093/ajcn/nqaa210" @default.
• W3048164517 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32766885" @default.
• W3048164517 hasPublicationYear "2020" @default.
• W3048164517 type Work @default.
• W3048164517 sameAs 3048164517 @default.
• W3048164517 citedByCount "8" @default.
• W3048164517 countsByYear W30481645172021 @default.
• W3048164517 countsByYear W30481645172022 @default.
• W3048164517 countsByYear W30481645172023 @default.
• W3048164517 crossrefType "journal-article" @default.
• W3048164517 hasAuthorship W3048164517A5016726863 @default.
• W3048164517 hasAuthorship W3048164517A5022380997 @default.
• W3048164517 hasAuthorship W3048164517A5022898660 @default.
• W3048164517 hasAuthorship W3048164517A5023538492 @default.
• W3048164517 hasAuthorship W3048164517A5037206327 @default.
• W3048164517 hasAuthorship W3048164517A5042375667 @default.
• W3048164517 hasAuthorship W3048164517A5052879720 @default.
• W3048164517 hasAuthorship W3048164517A5073182350 @default.
• W3048164517 hasAuthorship W3048164517A5079030452 @default.
• W3048164517 hasBestOaLocation W30481645171 @default.
• W3048164517 hasConcept C126322002 @default.
• W3048164517 hasConcept C140793950 @default.
• W3048164517 hasConcept C162156334 @default.
• W3048164517 hasConcept C185592680 @default.
• W3048164517 hasConcept C2778460671 @default.
• W3048164517 hasConcept C2908647359 @default.
• W3048164517 hasConcept C515207424 @default.
• W3048164517 hasConcept C55493867 @default.
• W3048164517 hasConcept C71924100 @default.
• W3048164517 hasConcept C86803240 @default.
• W3048164517 hasConcept C99454951 @default.
• W3048164517 hasConceptScore W3048164517C126322002 @default.
• W3048164517 hasConceptScore W3048164517C140793950 @default.
• W3048164517 hasConceptScore W3048164517C162156334 @default.
• W3048164517 hasConceptScore W3048164517C185592680 @default.
• W3048164517 hasConceptScore W3048164517C2778460671 @default.
• W3048164517 hasConceptScore W3048164517C2908647359 @default.
• W3048164517 hasConceptScore W3048164517C515207424 @default.
• W3048164517 hasConceptScore W3048164517C55493867 @default.
• W3048164517 hasConceptScore W3048164517C71924100 @default.
• W3048164517 hasConceptScore W3048164517C86803240 @default.
• W3048164517 hasConceptScore W3048164517C99454951 @default.
• W3048164517 hasIssue "5" @default.
• W3048164517 hasLocation W30481645171 @default.
• W3048164517 hasLocation W30481645172 @default.
• W3048164517 hasOpenAccess W3048164517 @default.
• W3048164517 hasPrimaryLocation W30481645171 @default.
• W3048164517 hasRelatedWork W1983335278 @default.
• W3048164517 hasRelatedWork W1986115866 @default.
• W3048164517 hasRelatedWork W2055707577 @default.
• W3048164517 hasRelatedWork W2184613897 @default.
• W3048164517 hasRelatedWork W2369183830 @default.
• W3048164517 hasRelatedWork W2416731870 @default.
• W3048164517 hasRelatedWork W2971136349 @default.
• W3048164517 hasRelatedWork W299615301 @default.
• W3048164517 hasRelatedWork W3048164517 @default.

• next